Elevated Circulating Insulin-Like Growth Factor Binding Protein-1 Is Sufficient to Cause Fetal Growth Restriction

Autor: Makoto Anzo, Carole S. Watson, Siu-Pok Yee, Peter Bialek, Javad Khosravi, Victor K. M. Han
Rok vydání: 2006
Předmět:
Time Factors
Placenta
Ligands
Polymerase Chain Reaction
Insulin-like growth factor-binding protein
Mice
Endocrinology
Tissue Distribution
Transgenes
Insulin-Like Growth Factor I
Phosphorylation
Promoter Regions
Genetic

In Situ Hybridization
Fetal Growth Retardation
biology
Reverse Transcriptase Polymerase Chain Reaction
Embryo
Immunohistochemistry
Blotting
Southern

medicine.anatomical_structure
Liver
embryonic structures
alpha-Fetoproteins
Genetically modified mouse
medicine.medical_specialty
DNA
Complementary

Transgene
Blotting
Western

Enzyme-Linked Immunosorbent Assay
Mice
Transgenic

In situ hybridization
Internal medicine
medicine
Animals
Humans
RNA
Messenger

DNA Primers
Fetus
Models
Statistical

Models
Genetic

Body Weight
Wild type
DNA
Blotting
Northern

Insulin-Like Growth Factor Binding Protein 1
Disease Models
Animal

Hepatocytes
biology.protein
RNA
Zdroj: Endocrinology. 147:1175-1186
ISSN: 1945-7170
0013-7227
DOI: 10.1210/en.2005-0606
Popis: IGF binding protein-1 (IGFBP-1) inhibits the mitogenic actions of the IGFs. Circulating IGFBP-1 is elevated in newborns and experimental animals with fetal growth restriction (FGR). To establish a causal relationship between high circulating IGFBP-1 and FGR, we have generated transgenic mice using the mouse α-fetoprotein gene promoter to target overexpression of human IGFBP-1 (hIGFBP-1) in the fetal liver. These transgenic mice (AFP-BP1) expressed hIGFBP-1 mainly in the fetal hepatocytes, starting at embryonic d 14.5 (E14.5), with lower levels in the gut. The expression peaked at 1 wk postnatally (plasma concentration, 474 ± 34 ng/ml). At birth, AFP-BP1 pups were 18% smaller [weighed 1.34 ± 0.02 g compared with 1.62 ± 0.04 g for wild type (WT); P < 0.05], and they did not demonstrate any postnatal catch-up growth. The placentas of the AFP-BP1 mice were larger than WT from E16.5 onwards (150 ± 12 for AFP-BP1 vs. 100 ± 5 mg for WT at E16.5; P < 0.05). Thus, this model of FGR is associated with a larger placenta, but without postnatal catch-up growth. Overall, these data clearly demonstrate that high concentrations of circulating IGFBP-1 are sufficient to cause FGR.
Databáze: OpenAIRE